Digital Symptom Monitoring Improves Outcomes in Patients on Oral Anticancer Drugs
The remote monitoring intervention reduced the rate of grade 3 or higher adverse events and the length of hospital stays.
The remote monitoring intervention reduced the rate of grade 3 or higher adverse events and the length of hospital stays.
Immunotherapy prolonged survival compared with platinum chemotherapy.
Having a high blood tumor mutational burden was associated with a significant improvement in response and a trend toward improvement in survival outcomes.
Segmentectomy prolonged 5-year overall survival in a phase 3 trial.
Adding nivolumab to chemotherapy improved the pathologic complete response rate and prolonged event-free survival.
The cumulative incidence of intracranial hemorrhage at 1 year was 22.5% in patients who received antiplatelet agents and 19.3% in those who did not.
Adding ipilimumab to pembrolizumab did not improve survival outcomes.
Overall survival was significantly longer for patients who received sintilimab plus chemotherapy than for those who received placebo plus chemotherapy.
Furmonertinib improved progression-free survival and appeared safer than gefitinib in a phase 3 trial.
Camrelizumab improved overall survival, even when adjusting for crossover.